tezosentan has been researched along with doxorubicin hydrochloride in 1 studies
| Studies (tezosentan) | Trials (tezosentan) | Recent Studies (post-2010) (tezosentan) | Studies (doxorubicin hydrochloride) | Trials (doxorubicin hydrochloride) | Recent Studies (post-2010) (doxorubicin hydrochloride) |
|---|---|---|---|---|---|
| 157 | 29 | 33 | 277 | 0 | 205 |
| Protein | Taxonomy | tezosentan (IC50) | doxorubicin hydrochloride (IC50) |
|---|---|---|---|
| RNA polymerase beta subunit (EC 2.7.7.6), partial | Escherichia coli | 14.3747 | |
| 90-kda heat shock protein beta HSP90 beta, partial | Homo sapiens (human) | 0.266 | |
| Apoptotic peptidase activating factor 1 | Homo sapiens (human) | 21.2 | |
| TPA: protein transporter TIM23 | Saccharomyces cerevisiae S288C | 12.7 | |
| caspase-9 isoform alpha precursor | Homo sapiens (human) | 34.6 | |
| caspase-3 isoform a preproprotein | Homo sapiens (human) | 34.6 | |
| heat shock protein HSP 90-alpha isoform 2 | Homo sapiens (human) | 0.266 | |
| 14-3-3 protein gamma | Homo sapiens (human) | 0.7812 | |
| DNA topoisomerase 2-alpha | Homo sapiens (human) | 0.94 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
1 other study(ies) available for tezosentan and doxorubicin hydrochloride
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |